{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-23-000028","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.271581+00:00","generated_at":"2026-06-13T00:27:48.347171+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie Q2 adj EPS $2.91 (-13.6%), rev $13.865B (-4.9%); raises FY adj EPS guidance to $10.90-$11.10","bullets":["GAAP diluted EPS $1.14 (+123.5% YoY); adjusted diluted EPS $2.91 (-13.6% YoY); includes $0.15 IPR&D impact.","Total net revenues $13.865B (-4.9% reported; -4.2% operational). Immunology $6.813B (-5.5%); Humira -25.2% to $4.012B.","Skyrizi +50.4% to $1.883B; Rinvoq +55.1% to $918M. Neuroscience +13.6% to $1.885B; Vraylar +33.9%.","Raised FY2023 adjusted diluted EPS guidance from $10.57-$10.97 to $10.90-$11.10; includes $0.23 IPR&D year-to-date."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-23-000028","json":"https://secwatch.observer/filing/0001551152-23-000028.json","markdown":"https://secwatch.observer/filing/0001551152-23-000028.md","text":"https://secwatch.observer/filing/0001551152-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/0001551152-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/abbv-20230727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:27:48.347171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30eb0de3d0c051a28d151fb4a02cec46162c9302","claim":"AbbVie Inc. reported the second quarter ended June 30, 2023 results: revenue $13.865 Billion, EPS $1.14. Guidance raised.","evidence_excerpt":"PRESS RELEASE AbbVie Reports Second-Quarter 2023 Financial Results • Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational Basis • Second-Quarter Global Net Revenues from the Immunology Portfolio Were $6.813 Billion, a Decrease of 5.5 Percent on a Reported Basis, or 5.0 Percent on an Operational Basis; Global Humira Net Revenues Were $4.012 Billion; Global Skyrizi Net Revenues Were $1.883 Billion; Global Rinvoq Net Revenues Were $918 Million • Second-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.478 Billion, a Decrease of 10.4 Percent on a Reported Basis, or 9.8 Percent on an Operational Basis; Global Imbruvica Net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/0001551152-23-000028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$13.865 Billion"},{"label":"EPS","value":"$1.14"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}